In this issue of Blood, Knittel et al report on the expression of MYD88 L265P in B lymphocytes of mice prone to neoplasms that resemble human diffuse large B-cell lymphoma (DLBCL). 1 T he frequent detection of a highly recurrent, oncogenic, gain-of-function mutation that substitutes a leucine (L) residue at position 265 of the adapter protein myeloid differentiation primary response gene 88 (MYD88) with a proline (P) residue has implicated the mutant
MYD88
L265P allele in the natural history and 
NF-κB TIRs

MYD88
L265P harbors a leucine-to-proline exchange in the hydrophobic core of its Toll/interleukin-1 receptor (TIR) domain (small red square), thus facilitating homotypic interaction with the TIR domain (small black square) of receptors from the TIR superfamily (TIRs). Upon recruitment of MYD88 to TIRs, MYD88 recruits interleukin 1 receptor-associated kinase 4 (IRAK4), which phosphorylates IRAK1 and -2 and promotes recruitment of tumor necrosis factor receptorassociated factor 6 (TRAF6). This results in ubiquitylation and activation of nuclear receptor subfamily 2 group C member 2, better known as TGF-b-activated kinase 1 (TAK1) and, ultimately, in activation of canonical NF-kB signaling. In a large group of patients in the German CML Study IV, 3.6% of patients had a major route ACA at diagnosis. 4 After a median observation period of 5.3 years, for patients with minor and major routes, the 5-year progression-free survival (PFS) was 96% and 50%, and the 5-year overall survival (OS) was 96% and 53%, respectively. In this trial exploring the value of different doses of imatinib and the combination of imatinib with interferon or cytarabine, the times to complete cytogenetic response (CCyR) and to major molecular response (MMR) were longer in patients with major route ACAs. A similar study was conducted by the Italian GIMEMA Working Party on CML. 5 Based on 559 patients enrolled into 3 different trials exploring 2 imatinib dosages (400 mg and 800 mg for different subgroups of patients according to Sokal score), ACAs at diagnosis were associated with worse outcome. In patients with major route ACAs, rates of CCyR and MMR were significantly inferior to those with only Ph translocation, and time to achieve CCyR and MMR were significantly longer. In contrast to the results of the German study, the Italian group did not observe differences between ACA patients and those without, when PFS and OS were considered. However, the current recommendation by the European Leukemia Net is to consider a major route ACA as a warning signal in patients treated frontline with TKI. 6 The detection of ACAs has been considered a feature of the accelerated phase (AP). But the World Health Organization includes ACAs a feature of the AP only if they are not present at diagnosis (ie, as evidence of clonal evolution). 7 In the current study, Wang et al revisited the relationship between ACAs detected in
